Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telomelysin - Oncolys Biopharma

Drug Profile

Telomelysin - Oncolys Biopharma

Alternative Names: OBP-301; Telomelysin; Telomerase-specific Type 5 Adenovirus OBP-301 - Oncolys Biopharma

Latest Information Update: 28 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncolys Biopharma
  • Developer Chugai Pharmaceutical; Cornell University; Medigen Biotechnology Corporation; Okayama University; Oncolys BioPharma
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses; Viral proteins
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gastric cancer; Malignant melanoma; Oesophageal cancer
  • Phase I/II Head and neck cancer; Liver cancer; Non-small cell lung cancer
  • Phase I Solid tumours
  • No development reported Adenoid cystic carcinoma; Breast cancer; Mesothelioma; Neuroblastoma; Osteosarcoma; Skin cancer; Soft tissue sarcoma

Most Recent Events

  • 28 May 2020 No recent reports of development identified for preclinical development in Neuroblastoma in Japan
  • 20 May 2020 National Cancer Institute plans a phase I trial for Oesophageal cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable)in July 2020 (NCT04391049)
  • 23 Apr 2020 Phase-II clinical trials in Oesophageal cancer in Japan (Intratumoural)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top